HC Wainwright reiterated their buy rating on shares of Merus (NASDAQ:MRUS – Free Report) in a research report sent to ...

Analysts at HC Wainwright lowered their FY2024 earnings estimates for shares of MediWound in a report released on Wednesday, ...

Fintel reports that on November 26, 2024, HC Wainwright & Co. downgraded their outlook for Poseida Therapeutics ...

Although it has lowered in recent days, commentators were mostly positive, with one hold and four buy recommendations on the stock. The consensus rating for the stock, as classified by MarketBeat, is ...

Wall Street expects Bitcoin miner CleanSpark Inc (NASDAQ:CLSK) to report a loss of 18 cents per share and $88.65 million in ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $28.0 to $50.0 for TG Therapeutics over the last 3 months. Looking at ...

On Friday, H.C. Wainwright maintained a Neutral rating and a $7.00 price target on Agenus Inc . (NASDAQ:AGEN), a biotechnology company currently valued at approximately $82 million. According to ...

Reiterates HC Wainwright & Co.: Neutral to Neutral 11/11/2024 Maintains HC Wainwright & Co.: Neutral to Neutral 8/12/2024 Reiterates HC Wainwright & Co.: Neutral to Neutral 6/17/2024 Maintains HC ...

as recommended by H.C. Wainwright. According to InvestingPro analysis, the stock appears undervalued at its current trading level. The reaffirmation came after IceCure Medical announced its third ...

After Amgen (AMGN) announced topline data from its Phase 2 study of MariTide, the company’s subcutaneously administered GLP-1 weight loss drug, H.C. Wainwright contends that Viking Therapeutics ...

H.C. Wainwright analyst Arthur He downgraded Poseida Therapeutics (PSTX) to Neutral from Buy with a price target of $9, down from $20, after Roche (RHHBY) agreed to acquire the company for $1.5B ...